UNSPSC 51152041: Orphenadrine

This classification denotes a muscle relaxant and antimuscarinic agent with the molecular formula C18H23NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier AL805O9OG9, chemically known as n,n-dimethyl-2-(o-methyl-.alpha.-phenylbenzyloxy)ethylamine hydrochloride but generally known as orphenadrine, which bears US NIH Compound Identifier 4601. European Medicines Agency schedules Orphenadrine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09471MIG.

UNSPSC 51152041 Orphenadrine is a Commodity code that captures pharmaceutical products procured by state and local health agencies. Recent state and local solicitations tagged under this code show activity in emergency medical supplies and community health initiatives, though the single recent opportunity on file diverges from the nominal scope — Seminole County, Florida's IFB60459723LAS solicits Naloxone and Safe Drug Deactivation Systems rather than orphenadrine specifically. State and local buyers under codes in this family typically include county health departments, community health agencies, and regional medical procurement offices serving public health missions.

Seminole County, Florida represents the only documented recent activity. The county issued IFB 60459723LAS on June 30, 2026, with a response deadline of July 26, 2023, seeking annual procurement of 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems with quarterly deliveries to the Seminole County Community Health Building in Sanford. The contract carries a two-year initial term with one-year renewal option, requires E-Verify compliance and drug-free workplace certification, and includes potential FEMA funding with attendant federal compliance requirements. Vendors must absorb all shipping and delivery costs in their bid price. The code shows limited recent activity in state and local procurement; the mismatch between the nominal commodity (orphenadrine) and the actual solicitation (naloxone and deactivation systems) suggests this code may not be the primary vehicle for orphenadrine procurement across state and local agencies, or that activity under it remains sparse.